MCL1 and cancer: Based on these findings, we speculated that those ER stress-activating agents may increase the expression of Noxa, leading to the reduction or inhibition of Mcl-1; and this characteristic may merit them as potential combination candidates with ABT-737 by exerting synergistic anti-cancer activities.